SPACs & vax: a BioCentury podcast 

Once much maligned, special purpose acquisition companies have become a viable path to the public markets for top-tier biotechs this year. On the latest BioCentury This Week podcast, BioCentury editors discuss what needs to happen for SPACs to become a cyclical part of biotech’s fund-raising equation. They also discuss the hurdles ahead for countermeasures against COVID-19.

For SPACs to be anything more than a fad, says BioCentury Associate Editor Virginia Li, the first several deals will need to make money for everyone involved. SPACs have been around for decades, but Li says the 2020 version being deployed by healthcare or biotech companies are not the same breed as the SPAC of 2005. ...